SLN124 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-transfusion-dependent Thalassemia
Conditions
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
Trial Timeline
Apr 14, 2021 → May 23, 2023
NCT ID
NCT04718844About SLN124 + Placebo
SLN124 + Placebo is a phase 1 stage product being developed by Silence Therapeutics for Non-transfusion-dependent Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04718844. Target conditions include Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05499013 | Phase 1/2 | Active |
| NCT04718844 | Phase 1 | Completed |
| NCT04559971 | Phase 1 | Completed |
Competing Products
2 competing products in Non-transfusion-dependent Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |
Other Products from Silence Therapeutics
SLN360 + PlaceboPhase 2
44
SLN124 + PlaceboPhase 1/2
33
Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2Phase 1/2
33
Atu027Phase 1
25
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboPhase 1
25